Yang et al. depicted the role of GPR120 in suppressing intestinal CD4+ T-cell induction of colitis through promoting the production of IL-10, suggesting the GPR120 agonist as a potential therapeutic target for treating IBD [233]; thus, targeting IL-10 may offer an alternative approach. Here, FFAR4 is linked to colitis.